Jennifer Lynn Leddon , MD,PhD

MD/PhD: University of Cincinnati

BS: University of Alabama Birmingham,

American Board of Internal Medicine (Certification Date: 08-16-2019 )

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-08-2023 )

Lung Cancer

Hematology and Oncology

Medical Oncology

Oncology

Internal Medicine

Medical Oncology

Grant: #CF33-hNIS-002 04-01-2022 -03-31-2025 Imugene Limited A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients Role:PI 721197.85 Hold Level:Industry

Grant: #CF33-hNIS-002 04-01-2022 -03-31-2025 Imugene Limited A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients Role:PI 721197.85 Hold Level:Industry

Grant: #NG-641-03 Investigators:Leddon, Jennifer 04-26-2023 -04-25-2026 Premier Research International LLC A multicentre, open-label, non-randomized, phase 1a/1b study of NG-641, a tumour-selective and transgene-expressing adenoviral vector, in combination with nivolumab in patients with metastatic or ad Role:PI 678371.74 Hold Level:Industry

Grant: #TAV0412 Investigators:Leddon, Jennifer 06-27-2023 -06-27-2026 Tavotek Biotherapeutics A 2-Part Open-Label Phase I Study of TAVO412 in Patients with Advanced or Metastatic Solid Tumors who progressed on prior approved standard of care therapy Role:PI 474391.93 Hold Level:Industry

Grant: #DF9001-001 Investigators:Leddon, Jennifer 08-24-2023 -08-24-2026 Dragonfly Therapeutics A phase 1/2 to InvestigateDF9001 in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications Role:PI 1492048.01 Hold Level:Industry

Grant: #PRESERVE-003 Investigators:Leddon, Jennifer 11-15-2023 -11-15-2026 OncoC4, Inc. Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors Role:PI 461365.32 Hold Level:Industry

Grant: #CA001-050 Investigators:Leddon, Jennifer; Riaz, Muhammad Kashif 09-01-2021 -08-31-2024 Bristol-Myers Squibb Co. A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Role:PI 532748.15 Active Level:Industry

Grant: #CF33-CD19-101 Investigators:Leddon, Jennifer 02-26-2024 -02-26-2027 Imugene Limited A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Ad Role:PI 1048337.24 Hold Level:Industry

Grant: #V940-002 Investigators:Leddon, Jennifer 06-12-2024 -06-12-2027 Merck Sharp & Dohme LLC A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants Role:PI 3971754.65 Active Level:Industry

Grant: #GMO221215; PO No.0000002543; Prime Grant No. G-18-100 Investigators:Leddon, Jennifer; Riaz, Muhammad Kashif 01-01-2022 -12-31-2024 Gateway for Cancer Research A Phase 2 Single-Center Pharmacodynamic Study of TVB-2640 in KRAS Mutant Non-Small Cell Lung Carcinomas Role:PI 30137.00 Active Level:Non Profit

Grant: #CA224-1093 Investigators:Leddon, Jennifer 12-23-2024 -12-23-2027 Bristol-Myers Squibb Co. A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Stage IV Role:PI 2533843.67 Hold Level:Industry

Published Abstracts

Leddon, J.L., Chen, C.Y., Currier, M.A., Wang, P.Y., Jung, F.A., Denton, N.L., Cripe, K.M., Haworth, K.B., Arnold, M.A., Gross, A.C. and Eubank, T.D. (2015. ) Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity .[Abstract]Molecular therapy oncolytics, 1 ,14010

Currier, M.A., Eshun, F.K., Sholl, A., Chernoguz, A., Crawford, K., Divanovic, S., Boon, L., Goins, W.F., Frischer, J.S., Collins, M.H. and Leddon, J.L. (2013. ) VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells .[Abstract]Molecular Therapy, 21(5) ,1014

Browne, A.W., Leddon, J.L., Currier, M.A., Williams, J.P., Frischer, J.S., Collins, M.H., Ahn, C.H. and Cripe, T.P. (2011. ) Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression .[Abstract]PloS one, 6(5) ,19530